News and Announcements
OncoSil Medical’s CEO Presents at ASX CEO Session
- Published November 17, 2015 4:37PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
17th November 2015, ASX Announcement
Developing implantable radiotherapy medical device
- 30 micron silicon particles contain beta emitting phosphorous (P32)
- Safer and stronger medical radiation treatment than external beam radiation
Successfully developed – preparing for EU commercialisation
- Four pilot clinical studies completed
-2 in primary liver/ hepatcellular carcinoma
-2 in pancreatic cancer - Excellent results to support Conformité Européene (CE) Marketing filings for both primary liver and pancreatic cancer & US FDA IDE submission
- Safety evaluations suggest that OncoSil is well tolerated in patients with unresectable primary liver and pancreatic cancer
- Efficacy data showed that OncoSil induces significant reduction in tumour volume in both liver and pancreas cancer and significantly reduces pain
To view the full presentation, please click here.